London, England, Nov. 10, 2018 – Cyberliver Ltd, a developer of cutting-edge solutions for liver care, today announced that Dr Gautam Mehta and team will present a poster at The Liver Meeting 2018 of the American Association for the Study of Liver Diseases held on Friday, November 9th through Tuesday, November 13th, at the Moscone North and South Convention Centre in San Francisco.
The poster is entitled “AlcoChange: A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease (Poster #1398) ” and will be presented on Sunday, November 11 2018, between 8:00 AM and 5:30 PM at Moscone Center, Hall C – Poster Hall.
Dr Gautam Mehta, Clinical Lead of the study, Consultant and Senior Lecturer in Hepatology at Royal Free Hospital said: “We are delighted to be presenting this study at The Liver Meeting 2018. These data demonstrate the potential of digital tools like AlcoChange to help manage alcohol-related liver disease (ARLD).” The AlcoChange clinical study, which ran from spring 2015 to end of 2017 at Royal Free London NHS Trust, supported by The Health Foundation and led by Prof Kevin Moore and Dr Gautam Mehta, clearly demonstrated that a smartphone app/breathalyzer can be used for self-monitoring and for Behavior Change Interventions (BCIs) in patients with ARLD, with a clear ‘dose-response’ amongst compliant patients. “Smartphone apps are a scalable intervention to help maintain abstinence in ARLD”
Commenting on the study, Prof Rajiv Jalan, Clinician Scientist, Prof of Hepatology, Head of Liver Failure group at UCL, said “the data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life”
Cyberliver is a company that focuses on delivering cutting-edge solutions for liver care via the use of innovative technology, based out of London, England, UK
AlcoChange is a patented Smartphone App/Breathalyzer platform, allows the monitoring of craving, alcohol consumption, and breath alcohol, and provides motivational messaging in response to patient triggers.
About AlcoChange Study:
For AlcoChange and CYBERLIVER Contact: RAVI KUMAR, [email protected]
FIRST FLOOR, BURNELLS, 5 GARLAND ROAD, STANMORE, MIDDLESEX, HA7 1NR, UNITED KINGDOM